It is early days for AOH1996, it could be that neither YF or...

It is early days for AOH1996, it could be that neither YF or anyone else knows its potential to be a valid treatment. Trials are needed to confim potential.. If the scientific brains in IMU think it has promise I don't see why they shouldn't pursue it. I don't know there foreward work load but presume they need new candidates as there existing drug trials mature. IMU say they don't want to go beyond phase 2.

From when I first looked at IMU I thought the biggest treat to its investment potential was competition from other companies developing products to treat cancer. Which is why I keep my eye out for what is happening in the oncology/cancer field. As far as I can make out IMU drugs are far better than current treatments and several years ahead in development of new generation drugs. The BP are not going to pause dealmaking for a few years because something better might crop up. If I was in there shoes, knowing more options were on the way I would reduce large up front payments and increase the royalty component of any deal to compensate to realities.
This is my imagination as to what is likely or should occur.